ifn

IFN alpha-IFNAR-IN-1 hydrochloride is an inhibitor of the interaction between IFN-α and IFNAR, effectively inhibiting MVA-induced IFN-α responses by BM-pDCs with an IC50 of 2-8 μM.

IFN alpha-IFNAR-IN-1 is a nonpeptidic, low-molecular-weight inhibitor that disrupts the interaction between IFN-α and IFNAR, inhibiting MVA-induced IFN-α responses by BM-pDCs (IC50: 2-8 μM).

IFN-α Receptor Recognition Peptide 1, associated with receptor interactions, is a peptide of IFN-α.

4-Methoxycinnamaldehyde (p-Methoxycinnamaldehyde) is an active ingredient of Agastache rugosa.4-Methoxycinnamaldehyde has cytoprotective activity against respiratory syncytial virus (RSV) in human laryngeal carcinoma cell lines, and helps to control disease induced by RSV infection, with an IC50 of approximately 0.055 μg/mL. The IC50 was about 0.055 μg/mL.

SM-276001 is a potent, selective agonist of TLR7 and an orally active interferon (IFN) inducer.

(R)-Lisofylline ((R)-Lisophylline) is an inhibitor of lysophosphatidic acid acyltransferase (IC50 = 0.6 µM) that interrupts IL-12 signaling-mediated STAT4 activation, making it useful for studies on the treatment of type 1 diabetes and autoimmune disorders.

Bufexamac (Bufexamic acid) is a COX inhibitor for IFN-α release with anti-inflammatory, analgesic, and antipyretic action.

(E)-Ferulic acid methyl ester (Methyl (E)-ferulate) is a potential inhibitor of the mitogen-activated phosphor kinase pathway and an anti-inflammatory agent first isolated from the medicinal plant S. tuberosa. Additionally, it shows promising anthelmintic activity against Haemonchus contortus.

CCCP (Carbonyl Cyanide m-Chlorophenylhydrazone) is an oxidative phosphorylation (OXPHOS) inhibitor and mitochondrial proton carrier uncoupler. CCCP inhibits the activation of STING and its downstream signaling molecules TBK1 and IRF3.

N-alpha-Tosyl-L-lysine chloromethyl ketone hydrochloride (N-alpha-Tosyl-L-lysine_chloromethyl_ketone_hydrochloride) is an inhibitor of trypsin-like protease and exhibits an inhibitory effect on IFN-γ activities.

GW9508(GW 9508) is a potent and selective agonist for FFA1 (GPR40), stimulates insulin secretion in a glucose-sensitive manner.

Cirsilineol (Eupatrin) is isolated from the herb of Artemisia vestita Wall and shows immunosuppressive, anti-proliferative, and anti-tumor properties. Cirsilineol selectively induces apoptosis via the mitochondrial pathway.

AX-024 hydrochloride (AX-024 HCl) is an cytokine release inhibitor which can strongly inhibit the production of interleukin-6 (IL-6), tumor necrosis factor-α (TNFα), interferon-γ (IFN-γ), IL-10 and IL-17A.

Sophocarpine, a major ingredient of Sophora alopecuroides, has a wide range of pharmacological effects.

Serplulimab (HLX 10) is a humanized monoclonal anti-antibody to PD-1. Serplulimab has antitumor activity and can be used in small cell lung cancer and esophageal squamous cell carcinoma.

Emapalumab (NI-0501) is an IgG1 monoclonal antibody that humanizes human monoclonal antibodies against interferon gamma, blocking its binding to cell surface receptors and activating inflammatory signaling. Emapalumab has a high binding force (Kd=1.4 pM) to free IFN-γ and to IFN-γ bound to its receptor. Emapalumab can be used in the study of hemophagocytic lymphohistiocytosis (HLH).

Sifalimumab (MEDI-545) is a monoclonal antibody that targets IFNα and suppresses abnormal immune activity by binding to interferon-alpha.Sifalimumab is used for the treatment of moderate to severe SLE.

Feladilimab (GSK3359609) is an IgG4 monoclonal antibody that is an ICOS agonist. Feladilimab binds to ICOS-expressing T cells, induces IFNγ, and increases PD-1/L1 expression. Feladilimab has anti-tumor activity and can be used to study cancer.

(Rac)-Benpyrine is a potent and orally active inhibitor of TNF-α.

AS1810722, a fused bicyclic pyrimidine derivative, is an orally active and potent inhibitor of STAT6, demonstrating an IC50 of 1.9 nM. It exhibits effective inhibition of CYP3A4, positioning it as a promising candidate for research into allergic diseases, including asthma and atopic conditions.

PD-1/PD-L1-IN-10 is an orally available PD-1/PD-L1 inhibitor (IC50 value of 2.7 nM) that shows anti-tumor activity.

Protosappanin A (PTA) has anti-oxidative/nitrative activities on brain immune and neuroinflammation through regulation of CD14/TLR4-dependent IKK/IκB/NF-κB inflammation signal pathway; it exerts anti-neuroinflammatory effect by inhibiting JAK2-STAT3 pathway in lipopolysaccharide-induced BV2 microglia. Protosappanin A induces immunosuppression of rats heart transplantation targeting T cells in grafts via NF-kappaB pathway. Protosappanin A and protosappanin B have antimicrobial activity, they show both alone activities and resistance reversal effects of amikacin and gentamicin against MRSA. Protosappanin A shows strong effect against HIV-1 IN with an IC50 value of 12.6 uM.

Ganoderic acid C1 has anti-inflammatory activity, has potential for treating TNF-α± mediated inflammation in asthma and other inflammatory diseases. Ganoderic acid C1 has anti-tumor-promoting activity. It is moderately active inhibitors against HIV-1 prot

Braylin has anti-inflammatory, antinociceptive and immunomodulatory effects, which possibly act through the glucocorticoid receptor activation and by inhibition of the transcriptional activity of NF-κB. Braylin is also a phosphodiesterase-4 inhibitor, it could represent an ideal prototype of glucocorticoid receptor ligand, able to induce synergic immunomodulatory effects.